- Home
- PSBD vs AMRN Comparison
PSBD vs AMRN Comparison
Compare PSBD & AMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
HOLD
Current Price
$15.81
Company Overview
Basic Information| Metric | PSBD | AMRN |
|---|---|---|
| Founded | 2009 | 1989 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 386.6M | 339.8M |
| IPO Year | 2024 | 1993 |
Fundamental Metrics
Financial Performance| Metric | PSBD | AMRN |
|---|---|---|
| Price | $12.01 | $15.81 |
| Analyst Decision | Hold | Strong Sell |
| Analyst Count | 5 | 1 |
| Target Price | ★ $13.30 | $12.00 |
| AVG Volume (30 Days) | ★ 140.7K | 95.1K |
| Earning Date | 02-26-2026 | 10-29-2025 |
| Dividend Yield | ★ 13.78% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $226,733,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $11.51 | $7.08 |
| 52 Week High | $16.16 | $20.90 |
Technical Indicators
Market Signals| Indicator | PSBD | AMRN |
|---|---|---|
| Relative Strength Index (RSI) | 46.90 | 60.58 |
| Support Level | $11.86 | $13.12 |
| Resistance Level | $12.28 | $14.33 |
| Average True Range (ATR) | 0.23 | 0.75 |
| MACD | -0.00 | 0.33 |
| Stochastic Oscillator | 44.34 | 75.00 |
Price Performance
Historical Comparison PSBD
AMRN
About PSBD Palmer Square Capital BDC Inc.
Palmer Square Capital BDC Inc is a financial services company that lends to and invests in corporate debt securities of companies, including small to large private U.S. companies. Their investment objective is to maximize total return, comprised of current income and capital appreciation.
About AMRN Amarin Corporation plc
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.